Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Hamilton Health Sciences AstraZeneca |
---|---|
Information provided by: | McMaster University |
ClinicalTrials.gov Identifier: | NCT00716963 |
The investigators propose a 3-treatment, placebo-controlled, double-dummy, double-blinded, randomized, crossover study in which single doses of placebo, will be compared to Fluticasone propionate (Flovent Diskus) 250 mcg and budesonide 400 mcg administered after allergen challenge, at cessation of the early allergic reaction (at 20% fall in FEV1 from post-allergen peak)
Condition | Intervention | Phase |
---|---|---|
Mild Asthma |
Drug: Fluticasone propionate (Flovent Diskus) 250 mcg Drug: budesonide 400 mcg Other: Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | Does a Lipophilic Steroid Inhaled After an Early Allergic Reaction Affect the Late Reaction? |
Enrollment: | 7 |
Study Start Date: | July 2008 |
Study Completion Date: | December 2008 |
Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Fluticasone propionate (Flovent Diskus) 250 mcg
|
Drug: Fluticasone propionate (Flovent Diskus) 250 mcg
Flovent Diskus 250 mcg
|
2: Active Comparator
budesonide 200mcg
|
Drug: budesonide 400 mcg
budesonide 400 mcg
|
3: Placebo Comparator
placebo
|
Other: Placebo
Placebo
|
The aim of this pilot study is to evaluate whether fluticasone propionate affects the late allergic reaction after a single dose post-allergen challenge administered following cessation of the early allergic reaction.
Six subjects with mild asthma will be asked to volunteer for the study.The diagnosis of asthma will be and includes the presence of variable airflow limitation and AHR (PC20 methacholine < 16 mg/mL). Subjects will be asked to participate if they demonstrate an allergen-induced early and late asthmatic response of at least 20% and 15% reduction in FEV1, respectively.
The study will consist of 4 periods, composed of a screening allergen period with 3 subsequent allergen challenge/treatment periods. Each period will be separated with a washout of at least 2 weeks. Subjects who demonstrate a dual asthmatic response in the screening period will be selected for randomization to treatment.
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Ontario | |
McMaster University | |
Hamilton, Ontario, Canada, L8N 3Z5 |
Principal Investigator: | Paul O'Byrne, MD | McMaster University |
Study Director: | Gail Gauvreau, PhD | McMaster University |
Responsible Party: | McMaster University ( Paul O'Byrne ) |
Study ID Numbers: | AZ2008lr |
Study First Received: | July 14, 2008 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00716963 History of Changes |
Health Authority: | Canada: Health Canada |
late allergic response fluticasone propionate |
Anti-Inflammatory Agents Hormone Antagonists Budesonide Hormones, Hormone Substitutes, and Hormone Antagonists Asthma Anti-Asthmatic Agents Anti-Allergic Agents |
Glucocorticoids Hormones Hypersensitivity Fluticasone Peripheral Nervous System Agents Bronchodilator Agents |
Anti-Inflammatory Agents Respiratory System Agents Immune System Diseases Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Budesonide Anti-Asthmatic Agents Anti-Allergic Agents Hormones |
Glucocorticoids Pharmacologic Actions Hypersensitivity Autonomic Agents Therapeutic Uses Fluticasone Peripheral Nervous System Agents Dermatologic Agents Bronchodilator Agents |